News
TRSBF
2.550
NaN%
--
3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate
TipRanks · 06/03 08:37
UBS Remains a Buy on 3SBio (TRSBF)
TipRanks · 05/30 00:34
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Kura Oncology (KURA) and 3SBio (OtherTRSBF)
TipRanks · 05/26 13:41
3SBio Moves to Replace Long-Standing Auditor EY With KPMG at 2026 AGM
TipRanks · 05/26 13:20
3SBio Shareholders Back Spin-Off Dividend of Mandi Inc. Shares
TipRanks · 04/23 13:12
Goldman Sachs Remains a Hold on 3SBio (TRSBF)
TipRanks · 04/06 15:45
3SBio (TRSBF) Gets a Buy from CMB International Securities
TipRanks · 04/02 05:20
Bank of China Remains a Buy on 3SBio (TRSBF)
TipRanks · 04/02 05:18
CICC Reaffirms Their Buy Rating on 3SBio (TRSBF)
TipRanks · 04/02 05:18
BOCOM International Holdings Company Remains a Buy on 3SBio (TRSBF)
TipRanks · 04/02 05:15
UBS Sticks to Its Buy Rating for 3SBio (TRSBF)
TipRanks · 04/02 00:39
Citi Reaffirms Their Buy Rating on 3SBio (TRSBF)
TipRanks · 04/02 00:38
3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend
TipRanks · 04/01 10:42
3SBio Plans Conditional Spin-Off Dividend via Mandi Inc. Share Distribution
TipRanks · 03/30 16:43
3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady
TipRanks · 03/30 16:05
3SBio Sets March Board Meeting to Approve 2025 Results and Weigh Mandi Spin-Off Payout
TipRanks · 03/17 09:42
CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)
TipRanks · 01/29 05:07
Goldman Sachs Remains a Hold on 3SBio (TRSBF)
TipRanks · 01/14 13:28
Morgan Stanley Reaffirms Their Buy Rating on 3SBio (TRSBF)
TipRanks · 01/13 11:12
3SBio (TRSBF) Gets a Buy from Guoyuan Securities (HK)
TipRanks · 01/05 05:05
More
Webull provides a variety of real-time TRSBF stock news. You can receive the latest news about 3Sbio through multiple platforms. This information may help you make smarter investment decisions.
About TRSBF
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.